GlobeNewswire

Treace Medical Concepts Reports Third Quarter 2026 Financial Results
06/11/2026
Achieved double digit procedure volume growth in the third quarter PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology [...]
Arch Biopartners Arranges Non-Brokered Private Placement
06/11/2026
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has arranged a non-brokered private placement offering of 1,058, [...]
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
06/11/2026
Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities RAMAT GAN, Israel, Nov [...]
Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy
06/11/2026
Financial advisory appointment to support planned acquisitions of profitable, revenue-generating businesses during 2027 DUBLIN, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “ [...]
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
06/11/2026
Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling Pharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluated Findings [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2 [...]
Notice of Annual General Meeting 2026
06/11/2026
The Annual General Meeting of Coloplast A/S will be held on Tuesday, 1 December 2026 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the [...]
Regenerative Ophthalmology Takes Center Stage This November 7 at the Next Generation Medicine Congress 2026 in Dubai
06/11/2026
DUBAI, United Arab Emirates, Nov. 06, 2026 (GLOBE NEWSWIRE) -- As the globe moves to the era of cellular restoration in healthcare, Next Generation Medicine Congress 2026 decided to dedicate November 7–10, 2026, to four [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
MIMEDX to Participate in Upcoming Investor Conferences
06/11/2026
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
06/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
06/11/2026
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products ( [...]
Curonix Freedom® Peripheral Nerve Stimulator (PNS) System Named Top New Pain Management Technology in Orthopedics This Week's Inaugural 2026 Awards
06/11/2026
POMPANO BEACH, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Curonix, a leading medical technology company dedicated to relieving chronic pain, today announced that the Freedom® Peripheral Nerve Stimulator (PNS) System has [...]
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
06/11/2026
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in early [...]
Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
06/11/2026
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will [...]
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
06/11/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 BOND-003 Cohort P and CORE-008 Cohort CX 12-month data [...]
Le KFSH de Riyad figure parmi les 5 % des meilleurs établissements de santé au monde pour le tourisme médical selon le classement 2027 de Newsweek
06/11/2026
RIYAD, Arabie saoudite, 06 nov. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) de Riyad se classe parmi les 5 % des meilleurs établissements de santé répertoriés dans l’édition [...]
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
06/11/2026
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum